Literature DB >> 14557645

Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization.

Jin-Won Youn1, Su-Hyung Park, Jae Ho Cho, Young Chul Sung.   

Abstract

Although DNA immunization is a safe and efficient method for inducing cellular immune responses, it generates relatively weak and slow immune responses. Here, we investigated the effect of hepatitis C virus (HCV) antigen modifications on the induction of T-cell responses in DNA immunization. It is likely that the strength of T-cell responses has an inverse relationship with the length of the insert DNA. Interestingly, a mixture of several plasmids carrying each gene induced a higher level of T-cell responses than a single plasmid expressing a long polyprotein. Moreover, the presence of a transmembrane domain in HCV E2 resulted in stronger T-cell responses against E2 protein than its absence. Taken together, our results indicate that the tailored modifications of DNA-encoded antigens are capable of optimizing the induction of T-cell responses which is required for eliminating the cells chronically infected with highly variable viruses such as HCV and human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557645      PMCID: PMC229347          DOI: 10.1128/jvi.77.21.11596-11602.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Enhancing DNA immunization.

Authors:  F Rodriguez; J L Whitton
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

2.  Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen.

Authors:  D R Drew; M Lightowlers; R A Strugnell
Journal:  Vaccine       Date:  2000-05-22       Impact factor: 3.641

Review 3.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

Authors:  J zur Megede; M C Chen; B Doe; M Schaefer; C E Greer; M Selby; G R Otten; S W Barnett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene.

Authors:  S W Lee; J H Cho; Y C Sung
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Polyvalent DNA vaccines with bidirectional promoters.

Authors:  M Kwissa; J Unsinger; R Schirmbeck; H Hauser; J Reimann
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

8.  Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins.

Authors:  L Cocquerel; C Wychowski; F Minner; F Penin; J Dubuisson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 9.  Vaccine development for hepatitis C.

Authors:  M Lechmann; T J Liang
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

10.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

View more
  8 in total

1.  Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier.

Authors:  Jia-Yu Chen; Fan Li
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  Molecular characterization and clinical epidemiology of HCV in District Dir (Lower), Pakistan.

Authors:  Sami Ullah; Muhammad Akram Khan; Shafiq Ur Rahman; Imran Khan; Fazal Akbar; Anshu Babbar
Journal:  Virusdisease       Date:  2018-05-17

3.  Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.

Authors:  Mi Suk Kim; Jeong-Im Sin
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

4.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

5.  Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Authors:  Jin-Won Youn; Yu-Wen Hu; Nancy Tricoche; Wolfram Pfahler; Mohamed Tarek Shata; Marlene Dreux; François-Loic Cosset; Antonella Folgori; Dong-Hun Lee; Betsy Brotman; Alfred M Prince
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

Review 6.  Therapeutic immunization for HIV.

Authors:  Lindvi Gudmundsdotter; Anna Sjödin; Ann-Charlotte Boström; Bo Hejdeman; Rebecca Theve-Palm; Annette Alaeus; Knut Lidman; Britta Wahren
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

7.  Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys.

Authors:  Su-Hyung Park; Mi-Young Song; Hyo Jung Nam; Se Jin Im; Young-Chul Sung
Journal:  Immune Netw       Date:  2010-12-31       Impact factor: 6.303

8.  In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine Design.

Authors:  Aqsa Ikram; Sadia Anjum; Muhammad Tahir
Journal:  Hepat Mon       Date:  2014-06-01       Impact factor: 0.660

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.